Edgeline Holdings announced yesterday that Dr. Donald Picker will be serving the Company’s subsidiary, Intertech Bio, as the Chief Operating Officer. He brings comprehensive hands-on experience with bringing drugs all the way from concept to clinical development.
Dr. Picker has previously held senior executive positions at leading companies where he was in charge of bringing many drug candidates into clinical development. Notably, he and his team were responsible for the development of Carboplatin, which is one of the world’s top cancer drugs presently utilized with annual sales of over $500 million.
Leonard Ivins, CEO of Edgeline Holdings, commented, “We are excited to have someone with Dr. Picker’s extensive experience and track record in oncology to lead the development of the cancer pipeline that Edgeline Holdings has identified for licensing. The ability to bring these candidates as quickly as possible into development should build value for the shareholders of the company.”
Let us hear your thoughts below: